In the fight against antimicrobial resistance, it is important to improve the diversity of therapeutic treatments to enable medical doctors to make the most appropriate choice. Eravacycline, a new antibiotic active substance, has recently been launched on the Belgian market.
As part of the fight against AMR, the FAMHP has developed a Belgian national action plan ‘One World, One Health’, in collaboration with the other Belgian public services involved. This plan is based on the three pillars of health: human health, animal health and the environment. It proposes concrete actions to combat antimicrobial resistance in a comprehensive and coordinated way. The FAMHP's activities are aimed at making new antimicrobials available and keeping older ones accessible. In this context, the FAMHP informs healthcare professionals of the recent placing on the market of one new antimicrobial medicine.
An eravacycline-based antibiotic (Xerava 100 mg) in powder for concentrate for solution for infusion has been on the market since 19 April 2024.
Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.
More information
• Package leaflet for Xerava 100 mg
• Summary of product characteristics for Xerava 100 mg
You can check the availability of all medicinal products (recently) marketed in Belgium via PharmaStatus.